Navigation
Company
Our Science
mTOR Pathway
TSC1
&
TSC2
nab
Technology Platform
Publications and Abstracts
Our Medicine
Our Medicine
Advanced Malignant PEComa
Pipeline
Patients
Overview
Patient Advocacy
Clinical Trials
Contact Us
General Contact
For Healthcare Professionals
Careers
Archive: November 20, 2019
Home
2019
November
20
20
Nov
2019
Mutational and Biomarker Correlative Analysis of mTOR Pathway Aberrations in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumors (PEComa) Treated With
nab
-Sirolimus: Results From AMPECT, an Open-Label Phase 2 Registration Trial
0
0
November 20, 2019
November 20, 2019